161 related articles for article (PubMed ID: 33080636)
1. Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the Risk.
Douxfils J; Morimont L; Bouvy C
Semin Thromb Hemost; 2020 Nov; 46(8):872-886. PubMed ID: 33080636
[TBL] [Abstract][Full Text] [Related]
2. Thrombin generation in first-degree relatives of patients with venous thromboembolism who have factor V Leiden. A pilot study.
Couturaud F; Duchemin J; Leroyer C; Delahousse B; Abgrall JF; Mottier D;
Thromb Haemost; 2008 Jan; 99(1):223-8. PubMed ID: 18217158
[TBL] [Abstract][Full Text] [Related]
3. Effects of oral contraceptives on hemostasis and thrombosis.
Rosing J; Tans G
Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S375-82. PubMed ID: 10368524
[TBL] [Abstract][Full Text] [Related]
4. Genetic Risk Factors of Venous Thromboembolism in the East Algerian Population.
Moussaoui S; Saussoy P; Ambroise J; Defour JP; Zouitene R; Sifi K; Abadi N
Clin Appl Thromb Hemost; 2017 Mar; 23(2):105-115. PubMed ID: 26304686
[TBL] [Abstract][Full Text] [Related]
5. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study.
Wu O; Robertson L; Langhorne P; Twaddle S; Lowe GD; Clark P; Greaves M; Walker ID; Brenkel I; Regan L; Greer IA
Thromb Haemost; 2005 Jul; 94(1):17-25. PubMed ID: 16113779
[TBL] [Abstract][Full Text] [Related]
6. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.
Price DT; Ridker PM
Ann Intern Med; 1997 Nov; 127(10):895-903. PubMed ID: 9382368
[TBL] [Abstract][Full Text] [Related]
7. Activated protein C resistance--a major risk factor for thrombosis.
Rosén SB; Sturk A
Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726
[TBL] [Abstract][Full Text] [Related]
8. Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception.
van Vlijmen EF; Veeger NJ; Middeldorp S; Hamulyák K; Prins MH; Büller HR; Meijer K
Blood; 2011 Aug; 118(8):2055-61; quiz 2375. PubMed ID: 21659542
[TBL] [Abstract][Full Text] [Related]
9. [Effects of second and third generation oral contraceptives on hemostasis].
Middeldorp S; Rosing J; Bouma BN; Büller HR
Ned Tijdschr Geneeskd; 2001 Feb; 145(6):252-6. PubMed ID: 11236370
[TBL] [Abstract][Full Text] [Related]
10. Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism.
Bennet L; Odeberg H
J Intern Med; 1998 Jul; 244(1):27-32. PubMed ID: 9698021
[TBL] [Abstract][Full Text] [Related]
11. Genetic risk factors for venous thromboembolism.
Zöller B; Svensson PJ; Dahlbäck B; Lind-Hallden C; Hallden C; Elf J
Expert Rev Hematol; 2020 Sep; 13(9):971-981. PubMed ID: 32731838
[TBL] [Abstract][Full Text] [Related]
12. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives.
Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Koster T; Bertina RM; Vandenbroucke JP
Thromb Haemost; 1998 Sep; 80(3):382-7. PubMed ID: 9759614
[TBL] [Abstract][Full Text] [Related]
13. Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism.
Heinemann LA; Assmann A; Spannagl M; Schramm W; Dick A; Kluft C; de Maat MP
Contraception; 1998 Nov; 58(5):321-2. PubMed ID: 9883389
[TBL] [Abstract][Full Text] [Related]
14. Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review.
Winkler UH
Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S51-61. PubMed ID: 9753311
[TBL] [Abstract][Full Text] [Related]
15. Oral contraception in women with mild thrombophilia: what have we learned recently?
Blanco-Molina Á
Thromb Res; 2012 Oct; 130 Suppl 1():S16-8. PubMed ID: 23026651
[TBL] [Abstract][Full Text] [Related]
16. Risk of thrombosis associated with oral contraceptives of women from 97 families with inherited thrombophilia: high risk of thrombosis in carriers of the G20210A mutation of the prothrombin gene.
Santamaría A; Mateo J; Oliver A; Menéndez B; Souto JC; Borrell M; Soria JM; Tirado I; Fontcuberta J
Haematologica; 2001 Sep; 86(9):965-71. PubMed ID: 11532625
[TBL] [Abstract][Full Text] [Related]
17. Does use of hormonal contraceptives among women with thrombogenic mutations increase their risk of venous thromboembolism? A systematic review.
Mohllajee AP; Curtis KM; Martins SL; Peterson HB
Contraception; 2006 Feb; 73(2):166-78. PubMed ID: 16413847
[TBL] [Abstract][Full Text] [Related]
18. The APC-PCI concentration as an early marker of activation of blood coagulation: a study of women on combined oral contraceptives.
Bremme K; Hamad RR; Berg E; Strandberg K; Stenflo J
Thromb Res; 2012 Oct; 130(4):636-9. PubMed ID: 22154243
[TBL] [Abstract][Full Text] [Related]
19. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives.
Aznar J; Vayá A; Estellés A; Mira Y; Seguí R; Villa P; Ferrando F; Falcó C; Corella D; España F
Haematologica; 2000 Dec; 85(12):1271-6. PubMed ID: 11114134
[TBL] [Abstract][Full Text] [Related]
20. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
